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Tatiane Correa1, Julie Teixeira da Costa1, Marco Aurélio Pinho de Oliveira1, 
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ABSTRACT
The objective is to evaluate knowledge on HPV vaccine and its use among university 
students. This is a cross-sectional study with 301 participants, of which 202 medical students 
from UERJ and UNIFESO (101 freshmen = M1 and 101 from the 6th year = M2) and 99 
UERJ literature students (50 freshmen = L1 and 49 of the last year = L2). Information was 
obtained by questionnaires. Input and statistical analysis were carried out with the EPI-INFO 
3.5.2 Program. Results showed that, among medical students, 21% of M1 and 16% of M2 
used the HPV vaccine (p=0.35), mostly adopted by women (M1=29.7% and M2=21.3%) 
than men (M1=5.4% and M2=7.5%). Similarly, female students showed more interest in 
using the vaccine (M1=85.1% and M2=80%) than male (M1=56.2% and M2=20.5%). Among 
literature students, only women received the vaccine (L1=6.5% and L2=22.2%) and no men 
were vaccinated (p=0.04). More women expressed interest in receiving the vaccine than men 
(♀ L1=76%, L2=65% and ♂ L1=47%, L2=40%). Comparison among genders regardless 
of the course showed that the vaccination rate is higher among women (p<0.001), as is the 
interest in being vaccinated (p=0.004). We concluded that the majority of male university 
students know less about the HPV vaccine than the female ones, use less and are less interested 
in being vaccinated, in all the groups interviewed. Vaccination coverage is low among the 
university population and is higher among medical students.
KEYWORDS: HPV. Vaccine. Primary prevention. HPV-related cancer. 
INTRODUCTION 
Human papillomavirus (HPV)-related neoplasms include cervical, vulvar, 
vaginal, penile, anal, rectal and oropharyngeal cancer1. More than 80% of HPV-
associated cancers affect the cervix, so most of the scientific evidence of vaccines 
is related to the cervical disease2.
There are currently three prophylactic HPV vaccines. Gardasil®, known as a 
tetravalent vaccine, which prevents infections from HPV types 6, 11, 16 and 18 
and is approved for women aged nine to 45 years and men aged nine to 26 years. 
Cervarix®, also called bivalent vaccine, is effective against HPV types 16 and 18 and 
is approved for women aged nine and over, with no upper age bracket3,4. Gardasil 9® 
vaccine provides coverage for nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, 58), 
showing potential coverage of approximately 90% of vulvar, vaginal, cervical and 
anal cancers. It is not currently marketed in Brazil3.
In March 2014, the Unified Health System (SUS) included the tetravalent HPV 
vaccine in the National Vaccination Program, targeting girls aged 11-13 years. It is 
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currently available for girls aged 9-14 years and boys aged 
11-14 years, in two doses with a 6-month interval. It is 
also available for people living with HIV, transplanted and 
oncological patients under chemotherapy and radiotherapy, 
aged 9-26 years, in three doses5.
From the beginning of vaccination until June 2017, 
18 million doses were applied to the female population 
nationwide. In the age group of 9-15 years, in the same 
period, 10.7 million girls received their first dose, which 
corresponds to 74.7% of the total Brazilian females in 
this age group. In total, 7.1 million girls received the 
full two-dose vaccination schedule recommended by the 
Ministry of Health, which corresponds to 47% of the target 
audience. Regarding boys, from January to June 2017, 
853,920 adolescents aged 12-13 years received their first 
dose of the HPV vaccine, which corresponds to 23.6% of 
the 3.61 million boys in this age group5. Thus, there is a 
lower vaccine demand than expected with low vaccination 
coverage.
The major challenge for public health is to develop 
accurate forms of communication and information about 
HPV so that people understand the importance of prevention 
and problems associated with this virus6. To this end, 
partnerships are being developed with scientific societies and 
joint work with churches, nongovernmental organizations 
and the media. The purpose is to clarify that HPV is a 
public health problem in the country and the importance of 
vaccination as the most relevant strategy to prevent cervical, 
vulvar, penile, anal and oropharyngeal cancer.
Accurate knowledge about HPV and its relationship 
with cervical cancer are critical to make appropriate, 
evidence-based health care choices. Knowledge levels of 
students studying at health care-related departments of 
medical colleges regarding cervical cancer, its risk factors, 
protection and HPV is important for both, the students and 
the society in which they will work7,8. Literature students 
will be future teachers. Teachers’ knowledge and attitudes 
towards the vaccine have been shown to significantly affect 
the success of HPV vaccination programs. Disseminating 
the correct information about the vaccine is key in ensuring 
community support9.
Due to the low vaccine coverage achieved, this study 
aimed to evaluate the level of knowledge and use of the 
HPV vaccine among university students.
METHODS 
This is a cross-sectional study on a population 
of university students consisting of 301 participants, 
distributed into groups of 202 medical students from UERJ 
and UNIFESO (101 freshmen = M1 and 101 from the 
6th year = M2) and 99 UERJ literature students (50 freshmen 
= L1 and 49 of the last year = L2). 
A structured questionnaire was distributed to literature 
and medicine students, and freshmen and last year students 
were interviewed. This questionnaire evaluated socio-
demographic data, life habits, sexual life information and 
contraception practice, knowledge about the “preventive” 
exam, knowledge about HPV-induced diseases and HPV 
vaccine (Figure 1).
The sample size calculation was based on the prevalence 
of 30% of HPV infection in sexually active populations10. 
In order to carry out the research, we used the total number 
of students enrolled in Medicine and Literature courses, 
which totalize 564 enrollments (282 per year). Assuming 
an alpha error of 0.05, the sample size of 206 students (103 
students in the first year and 103 in the last year) for the 
95% confidence interval were calculated. A convenience 
sample was used including all the students (regardless of 
gender) who agreed to participate. 
Ethical aspects 
The research project was conducted in accordance 
with the standards required by the Declaration of Helsinki 
and Resolution Nº 466 of the National Health Council 
of December 12, 2012. It was by the Research Ethics 
Committee of HUPE/UERJ in November 25, 2015 (Opinion 
Nº 1.337.349). The questionnaire was randomly applied 
and all those who agreed to participate signed the Informed 
Consent Form.
Data review 
The collected variables were used in the comparative 
analyses to identify prevalence ratios. Data were described 
by proportions, means, standard deviations, medians and the 
respective confidence intervals (CI) of 95% were estimated. 
The level of associations was evaluated by calculating 
association measures (odds ratio) and their respective 95% 
CIs. Data entry and statistical analysis was carried out with 
the EPI-INFO 3.5.2 Computational Program.
RESULTS 
Students’ profile 
In the group of medical students (M1 and M2), the 
mean age was 23.7 ± 4.2 years and 61.5% were female. As 
to ethnicity, 75% were Caucasian and approximately 95% 
were single. Of the group, 11.5% reported being smokers. 
Menarche occurred on average at 12.2 ± 1.3 years and 
Rev Inst Med Trop São Paulo. 2018;60:e46
Knowledge on the HPV vaccine among university students
Page 3 of 8
sexarch at 17.1 ± 2.5 years. The most used contraceptive 
methods were condoms (53% in M1 and 27% in M2) and 
combined oral contraceptive pills (COCP) (41.7% in M1 
and 47.9% in M2). Approximately 4% of M1 and 16% of 
M2 used no method at all. Over 60% of medical students 
reported only one sexual partner in the past three years.
In the group of literature students (L1 and L2), the 
mean age was 23.2 ± 6.4 years and more than 70% were 
female. More than half of the students have declared 
themselves Caucasians and more than 90% were single. 
Only 5% reported smoking. The mean age of menarche 
was 11.9 ± 1.7 years. First sexual intercourse occurred later, 
with a mean of 18.0 ± 2.8 years. Condoms and COCPs were 
also the most used methods, and in L1 condoms prevailed 
with 52%, and, in L2, COCPs were predominant, with 
44%. Around 85% of L1 and 64% of L2 reported using 
condoms at all times or sometimes, and these were the most 
significant numbers among the groups studied. Around 54% 
of L1 and 63% of L2 reported only one sexual partner in 
the last three years. (Table 1).
The first sexual intercourse occurred earlier in males 
(p<0.001, OR=0.37 [95% CI 0.22-0.62]) and occurred 
after the age of 16 in 54% of medical students and 79% of 
literature students.
Vaccine use
Among medical students, only 21% of M1 and 
16% of M2 used the HPV vaccine (p=0.35; OR=1.41 
[95% CI 0.68-2.93]). Comparing by gender, female medical 
students were vaccinated in greater numbers (M1=29.7% 
and M2=21.3%) than male students (M1=5.4% and 
M2=7.5%) (p<0.001, OR=4.92 [95% CI 1.92-14.87]). 
Among literature students, only women received the vaccine 
(L1=6.5% and L2=22.2%) and none of the males were 
vaccinated (p=0.04, OR=0.22 [95% CI 0.03-1.02]).
Interest in being vaccinated
Female medical students showed more interest in using 
the vaccine (M1=85.1% and M2=80%) than the boys’ 
group (M1=56.2% and M2=20.5%). Likewise, among 
literature students, more women expressed interest in 
receiving the vaccine (♀ L1=76%, L2=65% and ♂ L1=47%, 
L2=40%). However, the difference between courses was 
not statistically significant (p=0.68, OR=0.85 [0.37-1.86]) 
(Figure 2).
Gender comparison regardless of the course showed that 
the vaccination rate is higher in women (p<0.001, OR=0.19 
Figure 1 - Questionnaire applied to university students.
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[95% CI 0.06-0.47]), as is the interest in vaccination 
(p=0.004, OR=0.45 [95% CI 0.25-0.79]).
Who must be vaccinated 
In M1, 44% believe that only women should be 
vaccinated and 56% agree that both genders should have 
access. In M2, opinions are reversed. Among medical 
students, most believe that it should be administered only 
before the first sexual intercourse and most know that the 
age for vaccination by the SUS is between the ages of 9 
and 14. Literature students diverged on who should use the 
vaccine, since although 61% of L1 and 47% of L2 agree that 
it should be provided for both genders, 38% of L1 think it is 
only for women and 34% of L2 think that only men should 
use it. While slightly more than 50% of both groups agree 
Table 1 - Analysis of socio-demographic and sexual variables characteristics
1st year Med Last year Med 1st year Lit Last year Lit
Age (years) ≤ 24 83 (82.2%) 38 (37.3%) 41 (83.7%) 30 (61.2%)
>24 18 (17.8%) 64 (62.7%) 16 (3%) 19 (38. 8%)
Sex
Female 64 (63.3%) 61 (60%) 32 (64%) 38 (84.4%)
Male 36 (36.6%) 40 (39%) 18 (36%) 7 (15.6%)
Ethnicity
White 75 (75%) 81 (7.4%) 28 (56%) 28 (57.1%)
Mixed ethnicity or 
indigenous 16 (16%) 17 (16,6%) 12 (24%) 16 (32.7%)
Black 9 (9%) 4 (3.9%) 10 (20%) 5 (10.2%)
Marital status
Married/partnership 5 (5%) 6 (5.8%) 1 (2%) 7 (14.3%)
Not married 95 (95%) 96 (94.1%) 47 (95.9%) 42 (85.7%)
Smoking
Yes 9 (9%) 14 (13.8%) 2 (4.1%) 1 (2.1%)
No 91 (91%) 88 (86.2%) 47 (95.9%) 47 (97.9%)
Menarche (years) <12 17 (26.5%) 9 (25%) 15 (50%) 14 (37.8%)
≥12 47 (73.5%) 27 (75%) 15 (50%) 23 (62.2%)
Sexual debut (years) ≤16 31 (43%) 43 (45.7%) 11 (3.3%) 13 (33.3%)
>16 41 (57%) 51 (54.3%) 23 (67.7%) 31 (79.5%)
Contraceptive method
vaginal ring 0 (0%) 2 (2%) 0 (0%) 0 (0%)
hormonal IUD 0 (0%) 3 (3.2%) 0 (0%) 0 (0%)
Injectable 1 (1.2%) 0 (0%) 0 (0%) 0 (0%)
OHC 30 (41.7%) 45 (47.9%) 9 (26.5%) 18 (43.9%)
withdrawal 0 2 (2.1%) 1 (2.9%) 0 (0%)
condom 38 (52.8%) 26 (27.6%) 18 (52.9%) 15 (36.7%)
no methodi 3 (4.1%) 15 (16%) 6 (17.6%) 8 (19.5%)
Condom use
always 42 (60%) 30 (32%) 23 (67.6%) 19 (48.7%)
sometimes 18 (26%) 38 (40%) 6 (17.6%) 6 (15.8%)
never 9 (13%) 26 (27.6%) 5 (14.7%) 14 (35.9%)
Partners in the last 3 years
0 - 1 33 (61%) 36 (64.2%) 13 (54.2%) 17 (63%)
2 13 (24%) 10 (17.8%) 11 (45.8%) 10 (37%)
3 - 5 8 (14.8%) 10 (17.8%) 0 (0%) 0 (0%)
Med= Medicine; Lit= Literature; IUD= intrauterine device; OHC= oral hormonal contraceptive
Figure 2 - Interest in being vaccinated according to gender. 
Med= Medicine; Lit= Literature.
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that the vaccine should be given before the sexarch, 32% 
believe it can be used at any time. Most literature students 
know that the age for vaccination by the SUS is between 9 
and 14 years old (Table 2).
DISCUSSION
HPV infection has alarming proportions and is a 
predisposing factor for several types of cancers, including 
cervical, vaginal, anal and oropharyngeal cancer. From 
these data, it is possible to characterize HPV as a public 
health problem. The infection predominantly affects young, 
sexually active adults of both genders11.
In Brazil, data from the National Adolescent School-
based Health Survey (PeNSE) in 2009, in the Brazilian 
capitals, showed that, among adolescents aged 14 who have 
already had sexual intercourse, more than a third had their 
first sexual intercourse at 12 years old or less. Studies show 
that early sexual intercourse is associated with unprotected 
sex and more partners over a lifetime12.
This study was carried out with students of the first 
and last year of Medicine and Literature courses and the 
main results showed that most students did not know that 
vaccination could also be done after sexarch, and female 
students showed more interest in using the vaccine than male 
students in both groups (literature and medical students).
The mean age of the students was 23 years in both 
courses. As expected, most were single and young, up 
to 24 years of age. The first sexual intercourse occurred 
on average at the age of 17 among medical students and 
18 among literature students, and was earlier in males 
(p<0.001). These results are in agreement with two large 
Brazilian studies, the ERICA study with 74,589 Brazilian 
adolescents who showed the first sexual intercourse in 
28.1% of adolescents, with a higher prevalence around 17 
years old (56.4%) and in males (33.5%), and the National 
School Health Survey (PeNSE) conducted in 2012, which 
showed sexual activity in 28.7% (95% CI 26.4-31.2) of ninth 
grade students, usually aged 14 to 15 years, including 18.3% 
(95% CI: 15.3-21.8) of girls and 40.1% (95% CI 26.4-31.2) 
of boys12,13.
Regarding the use of contraceptive methods, freshmen 
of both courses reported condom use in 53%, with lower 
use among the last-year students (27.6% and 36.7%, 
respectively). Almost half of seniors use combined oral 
contraceptive pills (COCP). Based on this finding, it can 
be assumed that because graduating students are older, 
they are probably in a stable relationship. It is interesting 
to note that greater knowledge about sexually transmitted 
infections (STIs) and prevention of these diseases does not 
imply a greater use of the method, since the COCP is the 
most used method by M2, while condom is the most used 
method by M1.
For those who received the vaccine, the study showed 
that women were vaccinated in larger numbers than 
men, and that, among literature students, no males used 
Table 2 - Level of knowledge about HPV vaccine among medical and literature students
1st year Med Last year Med 1st year Lit Last year Lit 
Who should pay for 
vaccination?
Unified Health System 62 (61,3%) 81 (80%) 44 (88%) 44 (89,8%)
Others 27 (26,7%) 16 (15,8%) 1 (2%) 2 (4%)
Don't know 12 (11,8%) 4 (4%) 5 (10%) 3 (6,2%)
Who should get vaccinated?
Women 44 (44%) 57 (56,4%) 18 (38,3%) 9 (19,2%)
Men and women 56 (56%) 43 (42,5%) 29 (61,7%) 22 (46,8%)
Men 0 (0%) 1 (0%) 0 (0%) 16 (34%)
When vaccine should be 
given?
Before the sexarch 83 (83%) 76 (74,5%) 24 (51,1%) 26 (54,2%)
After the sexarche 0 (0%) 4 (3,9%) 3 (6,4%) 3 (6,3%)
Casual relashionship 1 (1%) 0 (0%) 4 (8,5%) 3 (6,3%)
If more than one partner 0 (0%) 0 (0%) 1 (2,1%) 0 (0%)
Any time 5 (5%) 11 (10,8%) 15 (31,9%) 16 (33,4%)
Age for vaccination by SUS
> 9 10 (10%) /6 (5,9%) 2 (4,5%) 5 (10,6%)
9 a 14 76 (76%) 76 (74,5%) 23 (52,3%) 24 (51%)
15 a 17 13 (13%) 11 (10,8%) 11 (25%) 13 (27,7&)
18 a 21 0 (0%) 1 (0%) 6 (13,6%) 3 (6,4%)
22 a 26 1 (1%) 0 (0%) 2 (4,5%) 1 (2,1)
Med=Medicine; Lit=Literature; SUS - Sistema Unico de Saude (Unified Health System)
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the vaccine. These results are similar to those of Yam et 
al.14 in Hong Kong, who found adherence to the vaccine 
of 45.2% of women and 8.8% of men. This can be 
attributed to the fact that the vaccine development and 
implementation strategy has been specifically focused 
on women with the aim of preventing cervical cancer, 
resulting in vaccine feminization15. In addition, women 
are the focus of procreative responsibility, thus bearing the 
burden of contraceptive liability. According to official data, 
the contraceptive pill is used by 27.4% of Brazilians, with 
sterilization appearing as the second contraceptive method, 
adopted by 25.9%. Vasectomy is less frequently reported, 
by only 5% of males16.
Low vaccine adherence in this study (less than 1/3 of 
all respondents) can also be explained by the fear of the 
ensuing risks of vaccination. This was also reported by Yam 
et al.14 who found that 33.1% of university respondents 
were concerned about the side effects of the HPV vaccine. 
A study conducted in Canada analyzing online comments 
on news sites to understand public perceptions of HPV17 
identified several negative comments regarding the 
composition of the vaccine, the unknown effects and as a 
cause of chronic diseases, showing a lack of knowledge of 
the population on the benefits of the vaccine.
Another hypothesis for the low number of vaccinees 
may be associated with the stigmatic and promiscuous 
view regarding the use of a vaccine that protects against 
STIs. Wong and Sam showed that 11.3% of women who 
did not receive the HPV vaccine reported shame of being 
vaccinated against STIs18.
Regarding the interest in being vaccinated, this study 
observed that more female students showed interest in 
using the vaccine in all groups. In general, students who 
are starting higher education are more interested in being 
vaccinated. This may be due to the relatively recent 
implementation of the HPV vaccine in Brazil, so that 
students still in the undergraduate years experienced more 
effectively vaccination campaigns and were aware of the 
importance of vaccination. In addition, as the focus of the 
campaign was the female audience, from the moment the 
government provided the vaccine for free in 2014, it was 
directed exclusively to women, and it was expected that 
the public would become more aware of and interested in 
vaccination19. The low interest of the male public may be 
partially attributed to the focus mostly given to cervical 
cancer in the HPV vaccine campaign, so that information 
such as the prevention of penile, anal, and oropharyngeal 
cancer had not been highlighted14.
In respect to those who should be vaccinated among 
Medicine and Literature freshmen, the view that both 
genders should have access to the vaccine prevailed, in 
last-year students of both courses most students believed 
that only women should be vaccinated. Once again, 
consideration should be given to the recent implementation 
of the HPV vaccine in Brazil and its vaccine campaign 
focused on women19. These data are in line with research 
conducted with students at a university in India20, which 
has shown that more than half of the students agree that 
only women should be vaccinated. This fact is worrisome, 
because men play a significant role in the transmission of 
the disease, since most of them have more sexual partners 
than women and, due to their low adherence to the tests, 
they end up not knowing that they have the disease.
Yam et al.14 observed that medical students, especially 
those most advanced in the course, had broader knowledge 
and positive attitudes about HPV vaccination, a behavior 
attributed to information received during university years, 
while students from other courses had less access to medical 
knowledge, and it was reasonable for these students to 
be less informed about HPV infection and its vaccine. 
However, when analyzing the vaccination practice in these 
two groups, there was no significant difference. On the 
other hand, our data showed that undergraduate students 
of the two courses have more knowledge about the vaccine 
than their veterans, while sixth-year medical students have 
shown a greater technical knowledge about HPV infection, 
associated pathologies and other aspects. Nonetheless, 
when analyzing the vaccination rate in these two groups, 
there was also no significant difference. The higher level of 
knowledge of students and health professionals about the 
HPV vaccine can contribute to an increased vaccination 
coverage, since they begin to have a positive perception, 
starting to recommend it to their patients. In an open letter to 
physicians, the Brazilian Society of Immunizations (SBIm), 
the Brazilian Society of Infectology (SBI), the Brazilian 
Society of Pediatrics (SBP) and the Brazilian Federation 
of Gynecology and Obstetrics Associations (FEBRASGO) 
have warned on how prescription of the HPV vaccine may 
change the current reality of low vaccine coverage. “Recent 
studies show that patients receiving recommendation 
from their doctors are four to five times more likely to get 
vaccinated. A hesitant, vague or sturdy recommendation 
may lead the patient to believe that the HPV vaccine is not 
as important as the others”21. This rationale is confirmed 
by a study that showed that students with higher levels of 
knowledge were more motivated to use and recommend 
vaccination22. A study conducted with medical students 
and physicians at the Federal University of Parana showed 
that more than half of the respondents would indicate the 
vaccine to boys and girls between the ages of 10 and 1523.
As for the vaccination timing, more than 80% of medical 
students and more than 50% of literature students believe 
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that the HPV vaccine should be given only before the 
sexarch. When implemented in the National Vaccination 
Program, the HPV vaccine targeted girls aged 11-13 years, 
an age range that was increased, and now covers girls aged 
9-14 years and boys aged 11-14 years19. This change aims 
to reach the public before the onset of the sexual life and, 
consequently, before the contact with the virus. However, 
the vaccine can be purchased in private clinics for the 
remaining individuals and is important to protect against 
HPV types that have not yet been acquired.
It is also possible to understand the importance of 
vaccination in women diagnosed with HPV to prevent new 
infections, since the subgroup undergoing prior vaccination 
evidenced a significant reduction in the incidence of 
subsequent HPV-related diseases, including severe lesions24.
One of the limitations of this study is that it is a 
cross-sectional study and the participants represented a 
convenience sample. After a pilot-testing questionnaire with 
ten students, we have changed some questions in order to 
facilitate reading and answering. It was found that dealing 
with questions directed to sexuality still generates certain 
discomfort and insecurity, especially for adolescents and 
young adults. Some participants have questioned, even after 
signing the Informed Consent Form, about the secrecy of 
the data and refused to respond after reading the content of 
the questionnaire. As the research included only students 
of medicine and literature, we cannot generalize the 
knowledge regarding HPV-induced diseases and the benefits 
of vaccination to the general public and to the universe of 
university students.
Thus, it is evident that, following what is expected 
in a wider context of dichotomization of vaccine use at 
a university level, male students are less knowledgeable 
about HPV vaccination than women, use less the vaccine 
and show less interest in being vaccinated in all groups 
interviewed. In addition, vaccination coverage is low 
among the university population and is higher among 
medical students. As already mentioned, it may be a result 
of the recent free implementation of the HPV vaccine 
in Brazil that did not include a large part of the public 
interviewed due to the age group, as well as the cost of 
the vaccine in private clinics. This reflects the difficulty 
of dealing with HPV as a collective health problem, and 
it is necessary to rethink its approach in order to achieve 
more solid and safe immunization rates for the population 
as a whole.
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